Rigel Pharma (RIGL) Misses Q4 EPS by 2c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. SPY
7. INTC
8. JBLU
9. NVDA
10. BA

Go back to Rigel Pharma (RIGL) Misses Q4 EPS by 2c, Revenues Miss

Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

February 27, 2020 4:01 PM EST

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

"We are entering 2020 with a clear plan to drive shareholder value for Rigel," said Raul Rodriguez, Rigel's president and CEO. "We see substantial opportunities for TAVALISSE to meet patient needs in the growing adult chronic ITP... More